R8404
Rufinamide
≥98% (HPLC), powder
Synonym(s):
1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C10H8F2N4O
CAS Number:
Molecular Weight:
238.19
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
powder
color
white
solubility
DMSO: 9 mg/mL
originator
Novartis
storage temp.
−20°C
SMILES string
NC(=O)c1cn(Cc2c(F)cccc2F)nn1
InChI
1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
InChI key
POGQSBRIGCQNEG-UHFFFAOYSA-N
Gene Information
Looking for similar products? Visit Product Comparison Guide
Application
Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.
Biochem/physiol Actions
Broad-spectrum anticonvulsant.
Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Diagnostic Implications
Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Carc. 2 - Repr. 2 - STOT SE 3
Target Organs
Central nervous system
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
K K Jain
Expert opinion on investigational drugs, 9(4), 829-840 (2000-11-04)
This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs, newly introduced AEDs and AEDs in clinical development. Pharmacological properties of 12
Emma D Deeks et al.
CNS drugs, 20(9), 751-760 (2006-09-07)
Rufinamide, a triazole derivative, reduces the recovery capacity of neuronal sodium channels after inactivation, limiting neuronal sodium-dependent action potential firing and mediating anticonvulsant effects. In children, adolescents and adults, adjunctive oral rufinamide was more effective than placebo in treating seizures
Paul L McCormack
PharmacoEconomics, 30(3), 247-256 (2012-02-16)
Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy
Marc R Suter et al.
Anesthesiology, 118(1), 160-172 (2012-12-12)
Voltage-gated sodium channels dysregulation is important for hyperexcitability leading to pain persistence. Sodium channel blockers currently used to treat neuropathic pain are poorly tolerated. Getting new molecules to clinical use is laborious. We here propose a drug already marketed as
Rainer Schimpf et al.
Heart rhythm, 9(5), 776-781 (2012-01-17)
The arrhythmogenic potential of short QT intervals has recently been highlighted in patients with a short QT syndrome. Drug-induced QT-interval prolongation is a known risk factor for ventricular tachyarrhythmias. However, reports on drug-induced QT-interval shortening are rare and proarrhythmic effects
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service